

2019-nCoV Spike protein RBD (N501Y) Catalog No: C19SD-G231H

SARS-CoV-2 variant, B.1.1.7 lineage, reported from the United Kingdom possess mutation N501Y at one of the six major contact residues in the receptor-binding domain involved in ACE2 binding. MD studies indicate that the mutant N501Y might increase the stability of the RBD domain with the ACE2 protein thereby resulting in higher virulence compared to the wild type strain. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization. SignalChem's Recombinant 2019-nCoV Spike protein S1 subunit, RBD (N501Y) (319-541) was expressed in CHO cells using a C-terminal his tag.

Unique Selling Points



Fully functional protein

1	$\bullet \bullet \bullet \bigcirc$
	$\bullet \bigcirc \bullet \bullet$
	$\bigcirc \bullet \bullet \bigcirc$
	$\bullet \bullet \bigcirc \bullet$

stratech.co.uk/signalchem info@stratech.co.uk

Stratech

Tested for activity using ELISA



Average purity determined to be 90%



Binding potency for hACE2

Competitors



RD SYSTEMS a biotechne brand



COVID19 ELISAs

COVID19

Protein Arrays

Applications



Diagnostic kits R&D





Recombinant antibody production Western Blot